文献速递肿瘤 PET/CT核素与放射性配体治疗

[18F]FDG PET/CT预测接受嵌合抗原受体T细胞治疗的弥漫大B细胞淋巴瘤患者的预后与毒性

[18F]FDG PET/CT for prognosis and toxicity prediction of diffuse large B-cell lymphoma patients with chimeric antigen receptor T-cell therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-03-12

该回顾性研究纳入38例接受抗CD19 CAR T细胞治疗的弥漫大B细胞淋巴瘤患者,在输注前3个月内和输注后1个月(M1)行[18F]FDG PET/CT,记录SUVmax、TLG、MTV及临床和实验室指标。中位随访18.2个月,M1时SUVmax、TLG和IPI是PFS的独立危险因素,M1时SUVmax和∆SUVmax%是OS的独立危险因素,并据此建立两个预测模型;输注前SUVmax与后续CRS严重程度相关。

要点

  • M1时SUVmax≥5.69、TLG≥23.79和IPI≥2的患者中位PFS更短。
  • M1时SUVmax≥15.93和∆SUVmax%≥-46.76的患者中位OS更短。
  • 输注前SUVmax与CRS分级强相关(rs=0.806,P<0.001)。

核心结论

  • 在该组接受CAR T细胞治疗的DLBCL患者中,M1时SUVmax、M1时TLG和IPI是PFS的独立危险因素,M1时SUVmax和∆SUVmax%是OS的独立危险因素。
  • 基于上述指标建立的两个预测模型经校准分析和决策曲线验证,对评估PFS和OS具有良好的效能。
  • 输注前SUVmax与后续任何CRS的严重程度相关,[18F]FDG PET/CT代谢参数可识别最可能从CAR T细胞治疗中获益的DLBCL患者,输注前的数值可能提前预测其毒性。

研究设计与样本

  • 回顾性研究,纳入38例接受CAR T细胞治疗并在输注前3个月内和输注后1个月(M1)行[18F]FDG PET/CT的DLBCL患者,定期随访。
  • 记录输注前和M1时间点的SUVmax、TLG、MTV、临床指数和实验室指标并计算其变化,以PFS和OS为终点。
  • 基于多因素Cox回归分析建立并评价两个PFS和OS预测模型,并用输注前指标预测细胞因子释放综合征(CRS)分级。

主要发现

  • 中位随访18.2个月,IPI≥2组中位PFS为8.1个月 vs IPI<2组26.2个月(P=0.025)。
  • M1时SUVmax≥5.69组中位PFS为3.1个月 vs SUVmax<5.69组26.8个月(P<0.001)。
  • M1时TLG≥23.79组中位PFS为3.1个月 vs TLG<23.79组26.8个月(P<0.001)。
  • M1时SUVmax≥15.93组中位OS为12.6个月 vs SUVmax<15.93组未达到(P<0.001);∆SUVmax%≥-46.76组中位OS为32.5个月 vs ∆SUVmax%<-46.76组未达到(P=0.012)。
  • 输注前SUVmax与CRS分级强相关(rs=0.806,P<0.001),输注前TLG与CRS分级中度相关(rs=0.534,P<0.001);输注前SUVmax与发生更高级别CRS的风险相关(P<0.001)。

关键数值与推荐

  • PFS的独立危险因素:M1时SUVmax、M1时TLG和IPI。
  • OS的独立危险因素:M1时SUVmax和∆SUVmax%。
  • PFS预测阈值:IPI≥2、SUVmax≥5.69、TLG≥23.79;OS预测阈值:SUVmax≥15.93、∆SUVmax%≥-46.76。
  • CRS分级与输注前SUVmax强相关(rs=0.806),与输注前TLG中度相关(rs=0.534)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Chimeric antigen receptor (CAR) T-cell therapy has been confirmed to benefit patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). It is important to provide precise and timely predictions of the efficacy and toxicity of CAR T-cell therapy. In this study, we evaluated the value of [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) combining with clinical indices and laboratory indicators in predicting outcomes and toxicity of anti-CD19 CAR T-cell therapy for DLBCL patients. METHODS: Thirty-eight DLBCL patients who received CAR T-cell therapy and underwent [18F]FDG PET/CT within 3 months before (pre-infusion) and 1 month after CAR T-cell infusion (M1) were retrospectively reviewed and regularly followed up. Maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG), metabolic tumor volume (MTV), clinical indices, and laboratory indicators were recorded at pre-infusion and M1 time points, and changes in these indices were calculated. Progression-free survival (PFS) and overall survival (OS) were as endpoints. Based on the multivariate Cox regression analysis, two predictive models for PFS and OS were developed and evaluated the efficiency. Pre-infusion indices were subjected to predict the grade of cytokine release syndrome (CRS) resulting from toxic reactions. RESULTS: For survival analysis at a median follow-up time of 18.2 months, patients with values of international prognostic index (IPI), SUVmax at M1, and TLG at M1 above their optimal thresholds had a shorter PFS (median PFS: 8.1 months [IPI ≥ 2] vs. 26.2 months [IPI < 2], P = 0.025; 3.1 months [SUVmax ≥ 5.69] vs. 26.8 months [SUVmax < 5.69], P < 0.001; and 3.1 months [TLG ≥ 23.79] vs. 26.8 months [TLG < 23.79], P < 0.001). In addition, patients with values of SUVmax at M1 and ∆SUVmax% above their optimal thresholds had a shorter OS (median OS: 12.6 months [SUVmax ≥ 15.93] vs. 'not reached' [SUVmax < 15.93], P < 0.001; 32.5 months [∆SUVmax% ≥ -46.76] vs. 'not reached' [∆SUVmax% < -46.76], P = 0.012). Two novel predictive models for PFS and OS were visualized using nomogram. The calibration analysis and the decision curves demonstrated good performance of the models. Spearman's rank correlation (rs) analysis revealed that the CRS grade correlated strongly with the pre-infusion SUVmax (rs = 0.806, P < 0.001) and moderately with the pre-infusion TLG (rs = 0.534, P < 0.001). Multinomial logistic regression analysis revealed that the pre-infusion value of SUVmax correlated with the risk of developing a higher grade of CRS (P < 0.001). CONCLUSION: In this group of DLBCL patients who underwent CAR T-cell therapy, SUVmax at M1, TLG at M1, and IPI were independent risk factors for PFS, and SUVmax at M1 and ∆SUVmax% for OS. Based on these indicators, two novel predictive models were established and verified the efficiency for evaluating PFS and OS. Moreover, pre-infusion SUVmax correlated with the severity of any subsequent CRS. We conclude that metabolic parameters measured using [18F]FDG PET/CT can identify DLBCL patients who will benefit most from CAR T-cell therapy, and the value before CAR T-cell infusion may predict its toxicity in advance.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Gui J, Li M, Xu J, et al. [18F]FDG PET/CT for prognosis and toxicity prediction of diffuse large B-cell lymphoma patients with chimeric antigen receptor T-cell therapy. Eur J Nucl Med Mol Imaging. 2024. PMID: 38467921. doi:10.1007/s00259-024-06667-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。